SCHEMBL3341235

SCHEMBL3341235

CCCCCC=C=CCCCCCCCCCC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.69
PPARD Q03181 9/20 0.69
PPARA Q07869 9/20 0.69
PTPN1 P18031 5/20 0.69
FABP4 P15090 4/20 0.69
TERT O14746 3/20 0.69
HSD17B10 Q99714 3/20 0.69
TDP1 Q9NUW8 3/20 0.69
MAPT P10636 2/20 0.69
BLM P54132 2/20 0.69
ALOX15 P16050 2/20 0.69
FABP5 Q01469 2/20 0.69
KMT2A Q03164 2/20 0.69
GMNN O75496 1/20 0.69
USP2 O75604 1/20 0.69
LMNA P02545 1/20 0.69
CYP1A2 P05177 1/20 0.69
POLB P06746 1/20 0.69
CYP2C9 P11712 1/20 0.69
APEX1 P27695 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9128942 1.00 PPARG (0.69) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL28183464 1.00 PPARG (0.69) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL8149939 1.00 PPARG (0.69) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL27779756 1.00 PPARG (0.69) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL29724318 1.00 PPARG (0.69) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1665622 0.96 TOP1 (0.67) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL11410056 0.96 F7 (0.69) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL18185533 0.87 PPARG (0.77) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL17540721 0.85 TERT (0.48) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL28849304 0.85 TERT (0.48) PPARGPPARDPPARAPTPN1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 US disclosed
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 US disclosed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 EP disclosed
US-20100151002-A1 Guggulphospholipid Methods and Compositions JINA PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
US-20050154059-A1 Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid WISCONSIN ALUMNI RESEARCH FOUNDATION 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151002-A1 Guggulphospholipid Methods and Compositions SGMS2, SGMS1, PLA2G5 PPARG 64/4885PPARD 305/4885PPARA 265/4885
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS SGMS1, SGMS2, GGPS1 PPARG 48/4885PPARD 305/4885PPARA 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.